Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine

3-Month follow-up

Ying Chieh Wang, Cheryl C H Yang, Ya Mei Bai, Terry B J Kuo

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance. Atypical antipsychotics have been used to treat schizophrenia patients since the 1990s, and more and more patients have been switched to these from typical antipsychotics; however, there is still no accessible evaluation tool for assessing cardiovascular safety. In this study, we used a computer-assisted 5-min measurement of resting heart rate variability (HRV) in schizophrenia patients who were switched to atypical antipsychotic agents (amisulpride and olanzapine) due to severe side effects (tardive dyskinesia). In 15 patients who switched to amisulpride and 18 to olanzapine, HRV was evaluated before the medication was switched, and patients were followed up every month for 3 months after the switch. Frequency-domain analyses of short-term and stationary respiratory rate (RR) intervals were performed to evaluate low-frequency power (LF; 0.04-0.15 Hz), high-frequency power (HF; 0.15-0.40 Hz), the ratio of LF to HF (LF/HF), and LF in normalized units (LF%). Our results showed significant increases in the mean, variance and HF of RR intervals in the amisulpride group, but not in the olanzapine group. These results indicate that amisulpride has a more vagotonic effect, suggesting greater cardiovascular safety as compared with olanzapine when subjects are switched from typical antipsychotic agents.

Original languageEnglish
Pages (from-to)200-205
Number of pages6
JournalNeuropsychobiology
Volume57
Issue number4
DOIs
Publication statusPublished - Sep 2008
Externally publishedYes

Fingerprint

olanzapine
Antipsychotic Agents
Heart Rate
Schizophrenia
Respiratory Rate
Safety
Mental Disorders
sultopride

Keywords

  • Antipsychotics
  • Heart rate variability
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Neuroscience(all)
  • Psychology(all)

Cite this

Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine : 3-Month follow-up. / Wang, Ying Chieh; Yang, Cheryl C H; Bai, Ya Mei; Kuo, Terry B J.

In: Neuropsychobiology, Vol. 57, No. 4, 09.2008, p. 200-205.

Research output: Contribution to journalArticle

@article{3324c9ac4ffd44ed914fa82ae8ccf177,
title = "Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine: 3-Month follow-up",
abstract = "Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance. Atypical antipsychotics have been used to treat schizophrenia patients since the 1990s, and more and more patients have been switched to these from typical antipsychotics; however, there is still no accessible evaluation tool for assessing cardiovascular safety. In this study, we used a computer-assisted 5-min measurement of resting heart rate variability (HRV) in schizophrenia patients who were switched to atypical antipsychotic agents (amisulpride and olanzapine) due to severe side effects (tardive dyskinesia). In 15 patients who switched to amisulpride and 18 to olanzapine, HRV was evaluated before the medication was switched, and patients were followed up every month for 3 months after the switch. Frequency-domain analyses of short-term and stationary respiratory rate (RR) intervals were performed to evaluate low-frequency power (LF; 0.04-0.15 Hz), high-frequency power (HF; 0.15-0.40 Hz), the ratio of LF to HF (LF/HF), and LF in normalized units (LF{\%}). Our results showed significant increases in the mean, variance and HF of RR intervals in the amisulpride group, but not in the olanzapine group. These results indicate that amisulpride has a more vagotonic effect, suggesting greater cardiovascular safety as compared with olanzapine when subjects are switched from typical antipsychotic agents.",
keywords = "Antipsychotics, Heart rate variability, Schizophrenia",
author = "Wang, {Ying Chieh} and Yang, {Cheryl C H} and Bai, {Ya Mei} and Kuo, {Terry B J}",
year = "2008",
month = "9",
doi = "10.1159/000149818",
language = "English",
volume = "57",
pages = "200--205",
journal = "Neuropsychobiology",
issn = "0302-282X",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - Heart rate variability in schizophrenic patients switched from typical antipsychotic agents to amisulpride and olanzapine

T2 - 3-Month follow-up

AU - Wang, Ying Chieh

AU - Yang, Cheryl C H

AU - Bai, Ya Mei

AU - Kuo, Terry B J

PY - 2008/9

Y1 - 2008/9

N2 - Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance. Atypical antipsychotics have been used to treat schizophrenia patients since the 1990s, and more and more patients have been switched to these from typical antipsychotics; however, there is still no accessible evaluation tool for assessing cardiovascular safety. In this study, we used a computer-assisted 5-min measurement of resting heart rate variability (HRV) in schizophrenia patients who were switched to atypical antipsychotic agents (amisulpride and olanzapine) due to severe side effects (tardive dyskinesia). In 15 patients who switched to amisulpride and 18 to olanzapine, HRV was evaluated before the medication was switched, and patients were followed up every month for 3 months after the switch. Frequency-domain analyses of short-term and stationary respiratory rate (RR) intervals were performed to evaluate low-frequency power (LF; 0.04-0.15 Hz), high-frequency power (HF; 0.15-0.40 Hz), the ratio of LF to HF (LF/HF), and LF in normalized units (LF%). Our results showed significant increases in the mean, variance and HF of RR intervals in the amisulpride group, but not in the olanzapine group. These results indicate that amisulpride has a more vagotonic effect, suggesting greater cardiovascular safety as compared with olanzapine when subjects are switched from typical antipsychotic agents.

AB - Schizophrenia is a severe mental disorder that requires lifelong treatment, and therefore information on the cardiovascular safety and tolerance of antipsychotics is of significant clinical importance. Atypical antipsychotics have been used to treat schizophrenia patients since the 1990s, and more and more patients have been switched to these from typical antipsychotics; however, there is still no accessible evaluation tool for assessing cardiovascular safety. In this study, we used a computer-assisted 5-min measurement of resting heart rate variability (HRV) in schizophrenia patients who were switched to atypical antipsychotic agents (amisulpride and olanzapine) due to severe side effects (tardive dyskinesia). In 15 patients who switched to amisulpride and 18 to olanzapine, HRV was evaluated before the medication was switched, and patients were followed up every month for 3 months after the switch. Frequency-domain analyses of short-term and stationary respiratory rate (RR) intervals were performed to evaluate low-frequency power (LF; 0.04-0.15 Hz), high-frequency power (HF; 0.15-0.40 Hz), the ratio of LF to HF (LF/HF), and LF in normalized units (LF%). Our results showed significant increases in the mean, variance and HF of RR intervals in the amisulpride group, but not in the olanzapine group. These results indicate that amisulpride has a more vagotonic effect, suggesting greater cardiovascular safety as compared with olanzapine when subjects are switched from typical antipsychotic agents.

KW - Antipsychotics

KW - Heart rate variability

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=48449085820&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48449085820&partnerID=8YFLogxK

U2 - 10.1159/000149818

DO - 10.1159/000149818

M3 - Article

VL - 57

SP - 200

EP - 205

JO - Neuropsychobiology

JF - Neuropsychobiology

SN - 0302-282X

IS - 4

ER -